SOPHiA GENETICS

SOPHiA GENETICS Announces Two Million Patient Cases Analyzed—A New Milestone for #DataDrivenMedicine! Yesterday at NVIDIA GTC, Jurgi Camblong, our Co-founder and CEO, took the stage to unveil a breakthrough: over 2 million patient genomic profiles analyzed. This historic milestone reflects the growing global impact of AI-powered precision medicine, with 800+ institutions across 72 countries leveraging the SOPHiA DDM? Platform to drive real-world impact in oncology and rare diseases. Our customers are at the heart of this success. We are honored to empower them: ?? "We have been using the SOPHiA DDM? Platform for nearly 10 years. Thanks to SOPHiA DDM?, the analysis of patients with hereditary cardiac pathologies at the second-largest university hospital in France is now faster and more efficient than ever. The Platform’s ease of use significantly enhances our ability to provide timely and accurate results. Thank you for empowering our institution to make an impact on countless lives among the two million genomic analyses,” said Gilles MILLAT, Gilles, University Lecturer, Hospital Practitioner, Hospices Civils de Lyon - HCL, France. ?? ?“Huge congratulations to SOPHiA GENETICS for reaching the incredible milestone of two million genomic analyses! Working together, we’ve brought advanced cancer diagnostics to more patients across India, including those in underserved communities. With the SOPHiA DDM? Platform, we’ve strengthened our ability to generate evidence and world-class research for faster and more accurate diagnosis, and we hope to expand it further in the coming years," added Dr. R.Venkataramanan, Founder, Karkinos Healthcare, India. The technology enables more effective and accurate treatment selection for cancer patients, at-scale: “SOPHiA DDM? allows us to tackle a wide range of genetic analyses at Fondazione Policlinico Universitario Agostino Gemelli, from exome sequencing to hereditary cancer and HRD testing, without compromising accuracy or efficiency,” explains Dr. Angelo Minucci, Head of Molecular and Genomic Diagnostics Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome, Italy.? "With SOPHiA DDM?, we have been able to confidently identify genetic rearrangements that provide critical insights into the complexity of cancer,” said Dr. Jessica Van Ziffle, Associate Professor, Department of Pathology & Associate Director, UCSF Clinical Cancer Genomics Lab, United States. ?? On this special occasion, we want to thank our partners from around the world. Their expertise and dedication are shaping our collective journey. Throughout the month, we will be sharing their experiences—stay tuned for more impactful stories! ?? Visit our website to read the full announcement and our co-founders’ reflections: https://lnkd.in/d7PRYypW Lars Steinmetz | Hutter Pierre #Media #Investors #BreakingNews #AIinHealthcare

Attending #BioITExpo in Boston? ?? Join our talk on Friday, April 4th from 12:10 to 12:40 PM, by Paul Bernard, Data Engineer – Multimodal R&D, to learn how SOPHiA DDM? for Multimodal is transforming the future of cancer care, with AI-driven analytics. ?? Add to calendar: https://loom.ly/BSBTx2k #BioITExpo #AI #PrecisionMedicine #DataDrivenMedicine #Oncology

The 2025 Emerging Leader Training season has officially begun! ?? At SOPHiA GENETICS, we are committed to developing the next generation of leaders who will drive collaboration, performance, and innovation in data-driven medicine. Our Emerging Leader Training Program equips talent across all departments with the skills to lead with impact as we continue our mission to democratize #DataDrivenMedicine. This season kicked off strong with our first 2025 session in our brand-new Boston Office! Huge thanks to Daniel Becker, CPA, Daniel Hirsch, Sophie Mannai, Alexandra Buga, Jonathan Vargas, Karen Schindler and Aaron Hersum for their participation, and to Julie Romain for building and facilitating this incredible program. ?? We'll continue investing in leadership today to shape the future of healthcare tomorrow! #EmergingLeaders #LeadershipDevelopment #TeamGrowth #Boston

From 1 million to 2 million patient cases analyzed—driven by people, purpose, and a bold belief that data can empower healthcare professionals. ? In 2022, we reached our first million. Just three years later, 2 million analyses have been run on SOPHiA DDM?—each one helping to bring smarter, faster, and more equitable care to patients around the world. ? From Bidart to Pessac, Boston to Rolle, and across every remote location of our global team—we continue to think globally and act regionally, with impact at the core. This journey started with?Zhenyu, Adam, and myself—three people and one shared mission. ? Now, I'm proud to say this milestone belongs to our customers, people, and partners. ? The spotlight and attention from around the world have been incredible—for me and for everyone at SOPHiA GENETICS. And we’re just getting started! ? Stay close. The next chapter is already taking shape.

??? Fresh off the Swiss press in 24 heures: SOPHiA GENETICS in the spotlight for reaching 2 million patient cases analyzed with SOPHiA DDM?. Dr. Jurgi Camblong, our Co-founder & CEO, and Dr. Philippe Menu, our Chief Medical Officer and Chief Product Officer, are featured for their insights on how AI-powered, multimodal analysis is reshaping patient care. The article highlights the real-world impact of our platform and our commitment to making data-driven medicine more accessible across the globe. Thank you to Alain Detraz for the meaningful coverage! ?? Read here (under paywall): https://lnkd.in/dSn8u94h #DataDrivenMedicine #Genomics #HealthInnovation #AIinHealthcare #MultimodalData #Media

As part of our milestone celebrating 2 million patient cases analyzed with the SOPHiA DDM? Platform, we’re honored to spotlight one of our long-standing partners in oncology research and care. Thank you to Prof. Hagay Sobol, Coordinator of the Department of Cancer Biology, Head of Molecular Oncogenetics, Institut Paoli-Calmettes / Aix-Marseille University, for your continued trust and collaboration. This milestone reflects the incredible work done every day by world-class institutions across the globe. To all our customers and partners—thank you. We’ll be sharing more impactful perspectives from our community throughout the month—stay tuned! ?? Learn more about the SOPHiA DDM? Platform: https://loom.ly/2IponFw #DataDrivenMedicine #PrecisionOncology #AIinHealthcare #Media

Next stop… Boston! ?? Meet us at the 24th Annual Bio-IT World Conference & Expo, in Boston, MA, April 2-4. Join us at booth #724 to learn how we help BioPharma companies overcome drug development challenges with tailored data solutions, accelerating the development of precision therapies. Learn more about the event from our website: https://loom.ly/f8TxnUs #BioITExpo #AI #PrecisionMedicine #DataDrivenMedicine #Oncology

We are excited to announce our latest Article Spotlight: Addition of Radiomic Features Improves the Prediction of Lung Toxicity Occurrence After (Chemo) radiotherapy. ?? Dive into this collaboration with Tenon Hospital, Greater Paris University Hospitals - AP-HP, led by Dr. Eleonor Rivin del Campo, and discover how adding radiomic features with SOPHiA DDM? for Radiomics, to clinical and dosimetric data enhances the prediction of acute lung toxicity in patients receiving radiotherapy for lung cancer. ?? Read the spotlight on our website: https://loom.ly/knwp3Bw #AIinHealthcare #DataDrivenMedicine #MachineLearning #AI #OncologyResearch #LungCancer

In my talk at NVIDIA GTC last week, I had the opportunity to share a key milestone for data-driven medicine: Over 2 million genomic profiles analyzed through SOPHiA DDM?. ? The next day, Kimberly Powell, Vice President of Healthcare at NVIDIA, spoke about the evolution of AI in medicine—highlighting partners and key players across the ecosystem, including SOPHiA GENETICS. ? From our roots at EPFL to a global platform empowering over 800 world-class healthcare institutions, this is a proud moment for our team. Our achievements reflect the trust of our partners and the scale of our shared mission. ? At ACMG - American College of Medical Genetics and Genomics in Los Angeles, momentum continued.? ? Conversations with leading researchers and clinicians confirmed the growing need for real-world #AI that scales and drives impact in clinical genomics. ? I am energized by what’s ahead and eager to expand across the tech partner landscape! #AIinHealthcare

?? DEEP-Lung-IV study: A deep learning approach to understand NSCLC prognosis and treatment responses SOPHiA GENETICS’ DEEP-Lung-IV (NCT04994795), a multicentric and multimodal real-world data observational study, is focused on unraveling predictive signatures linked with immunotherapy treatment responses and prognosis in stage IV NSCLC patients. We are excited to share our recent interview with Prof. Jacques Cadranel, MD - Oncologist, Head of the Department of Pneumology at Greater Paris University Hospitals - AP-HP Tenon Hospital, and Prof. Sébastien Couraud, MD - Oncologist, Head of the Pulmonology and Thoracic Oncology Department at Hospices Civils de Lyon - HCL, where you can learn more about how multimodal data integration is advancing personalized medicine in lung cancer. ?? Watch the video to discover the DEEP-Lung-IV study and learn more on our website: https://lnkd.in/dYFsYANi #ELCC?#PrecisionMedicine?#LungCancer?#DataDrivenMedicine?#Oncology?#MultimodalAnalysis Marion Brayer